Related Experiment Video
Updated: Aug 11, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
TNF-α is associated with low phase angle in male patients with chronic hepatitis C
Thais Pontello de Vries1, Aline Marcos Pires1, Fernanda Gomes Camilo2
1Sciences Applied to Adult Health Care Post-Graduate Programme, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil; Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Insights
Phase angle (PhA) may indicate systemic inflammation in male chronic hepatitis C (CHC) patients. Lower PhA correlates with higher tumour necrosis factor alpha (TNF-α) levels, suggesting PhA
Area of Science:
- Hepatology and Immunology
- Biomarker Discovery
- Nutritional Science
Background:
- The role of Phase angle (PhA) as a systemic inflammation biomarker in chronic hepatitis C (CHC) is not well understood.
- Identifying reliable biomarkers for inflammation and nutritional status in CHC is crucial for patient management.
Purpose of the Study:
- To investigate the association between PhA values and tumour necrosis factor alpha (TNF-α) in CHC patients.
- To explore correlations between PhA and demographic, clinical, nutritional, and biochemical factors in CHC.
Main Methods:
- Cross-sectional study of 81 CHC patients (mean age 50.0 ± 11.7 years).
- Body composition assessed via anthropometry and bioelectrical impedance analysis (BIA).
- Serum TNF-α measured by ELISA; logistic regression used for analysis.
Main Results:
- Reduced PhA was found in 14.8% of CHC patients.
- In male patients, reduced PhA was independently linked to elevated TNF-α levels (OR: 1.21; 95% CI: 1.06-1.39).
- No significant association between PhA and TNF-α was observed in female patients.
Conclusions:
- Lower PhA values in male CHC patients are associated with elevated TNF-α levels, irrespective of liver disease severity.
- PhA shows potential as a practical screening tool for systemic inflammation and nutritional risk in CHC.
- Integrating PhA assessment into routine care could benefit healthcare settings for CHC patients.
Background:
The potential role of Phase angle (PhA) as a biomarker of systemic inflammation in chronic hepatitis C (CHC) remains underexplored.
Objective:
To assess the association between PhA values and the inflammatory marker-tumour necrosis factor alpha (TNF‑α) in patients with CHC. In addition, associations between PhA and a set of demographics, clinical, nutritional, and biochemical data were evaluated.
Methods:
This cross-sectional study included 81 adults with confirmed CHC (72.8% male; mean age 50.0 ± 11.7 y; 30.9% with liver cirrhosis). Nutritional status and body composition were assessed using anthropometry and bioelectrical impedance analysis (BIA). Reduced PhA was defined as ≤5.6° for men and ≤5.4° for women. Serum TNF-α concentrations were measured using an enzyme-linked immunosorbent assay (ELISA), including 81 and 39 samples from patients with CHC and healthy donors, respectively. Logistic regression analyses were conducted to evaluate associations between PhA and inflammatory, demographic, clinical, nutritional, and biochemical variables.
Results:
Reduced PhA was observed in 14.8% of participants. Among male patients, reduced PhA was independently associated with elevated TNF-α levels (OR: 1.21; 95% CI: 1.06-1.39). However, no significant associations were found in the female patients.
Conclusions:
Male patients with CHC who present lower PhA values also exhibit elevated TNF‑α levels, independent of liver disease stage. Given the clinical relevance of identifying systemic inflammation and nutritional risk in this population, integrating a practical and reliable screening tool, such as PhA, into routine care may provide substantial value in health care settings.
Related Concept Videos
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Hepatitis
